4//SEC Filing
Hite Christopher 4
Accession 0000950103-20-012252
CIK 0001802768other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 9:13 PM ET
Size
11.2 KB
Accession
0000950103-20-012252
Insider Transaction Report
Form 4
Hite Christopher
EVP & Vice Chairman
Transactions
- Purchase
Class A Ordinary Shares
2020-06-18$28.00/sh+70,000$1,960,000→ 70,000 total - Award
ICAI Interests
2020-06-15+116,100→ 116,100 totalExercise: $0.00→ Limited Partnership interests in RPI US Partners 2019, LP (116,100 underlying) - Award
LP interests in RPI US Partners 2019, LP
2020-06-15+62,500→ 62,500 totalExercise: $0.00→ Class A Ordinary Shares (625,000 underlying)
Footnotes (4)
- [F1]The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020.
- [F2]Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.
- [F3]These RPI US LP Interests are subject to one-year vesting, with 100% of the interests vesting on March 22, 2021.
- [F4]These ICAI Interests represent a grant of up to 116,100 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share.
Documents
Issuer
Royalty Pharma plc
CIK 0001802768
Entity typeother
Related Parties
1- filerCIK 0001814238
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 9:13 PM ET
- Size
- 11.2 KB